Lineage Cell Therapeutics (LCTX) Acquisitions (2010 - 2019)
Lineage Cell Therapeutics (LCTX) posted quarterly Acquisitions of $3.1 million for Q1 2019, up 966.05% quarter-over-quarter from $292387.0 in Q2 2012.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Acquisitions (2010 - 2019) Analysis & Trends
Lineage Cell Therapeutics' Acquisitions history runs 4 years deep, the most recent figure standing at $3.1 million for Q1 2019.
- In Q1 2019, Acquisitions changed N/A year-over-year to $3.1 million; the TTM figure through Dec 2019 stood at $3.1 million (changed N/A YoY), while the FY2019 annual figure was $3.1 million, changed N/A from the prior year.
- Acquisitions for Q1 2019 stood at $3.1 million, up from $292387.0 in the prior quarter.
- The five-year high for Acquisitions was $3.1 million in Q1 2019, with the low at $3.1 million in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2019 | 3.12 Mn |
| Jun 30, 2012 | 292,387.00 |
| Mar 31, 2011 | 246,850.00 |
| Dec 31, 2010 | 222,766.00 |